Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

[1]  D. Bishop,et al.  A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis , 2011, Cancer Prevention Research.

[2]  R. Kucherlapati,et al.  Aspirin and Low-Dose Nitric Oxide–Donating Aspirin Increase Life Span in a Lynch Syndrome Mouse Model , 2011, Cancer Prevention Research.

[3]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[4]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[5]  A. Algra,et al.  Long-term eff ect of aspirin on colorectal cancer incidence and mortality : 20-year follow-up of fi ve randomised trials , 2010 .

[6]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[7]  J. Baron,et al.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.

[8]  R. Pearson.  Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome , 2009 .

[9]  D. Bishop,et al.  Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. , 2008, The New England journal of medicine.

[10]  D. Bishop,et al.  Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Vasen.  Can the Identification of High Risk Groups Increase the Effectiveness of Colon Cancer Screening Programmes? , 2008, Zeitschrift fur Gastroenterologie.

[12]  L. Kopelovich,et al.  Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. , 2007, Cancer research.

[13]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[14]  P. Rothwell,et al.  Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.

[15]  P. Møller,et al.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) , 2007, Journal of Medical Genetics.

[16]  P. Rothwell,et al.  Eff ect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies , 2007 .

[17]  B. Leggett,et al.  Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. , 2002, European journal of cancer.

[18]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[19]  J. Rüschoff,et al.  Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Schuler.  Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.

[21]  J. Jass,et al.  Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? , 1995, Seminars in surgical oncology.